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Pmino-Terminal Pro-B-Type
atriuretic Peptide and B-Type
atriuretic Peptide in the General Community
eterminants and Detection of Left Ventricular Dysfunction
isa C. Costello-Boerrigter, MD, PHD,*† Guido Boerrigter, MD,* Margaret M. Redfield, MD,*†
ichard J. Rodeheffer, MD,† Lynn H. Urban, MS,‡ Douglas W. Mahoney, MS,‡
teven J. Jacobsen, MD, PHD,§ Denise M. Heublein, CLT,* John C. Burnett, JR, MD*†
ochester, Minnesota
OBJECTIVES This study sought to characterize factors influencing amino-terminal pro-B-type natriuretic
peptide (NT-proBNP) and to evaluate the ability of NT-proBNP to detect left ventricular
(LV) dysfunction in a large community sample.
BACKGROUND Secretion of BNP increases in cardiac disease, making BNP an attractive biomarker.
Amino-terminal proBNP, a fragment of the BNP prohormone, is a new biomarker. We
evaluated factors influencing NT-proBNP in normal patients and compared the ability of
NT-proBNP and BNP to detect LV dysfunction in a large community sample.
METHODS Amino-terminal pro-BNP was determined in plasma samples of a previously reported and
clinically and echocardiographically characterized random sample (n 1,869, age 45 years)
of Olmsted County, Minnesota.
RESULTS In normal patients (n  746), female gender and older age were the strongest independent
predictors of higher NT-proBNP. Test characteristics for detecting an LV ejection fraction
40% or 50% were determined in the total sample with receiver operating characteristic
curves. Amino-terminal pro-BNP had significantly higher areas under the curve for detecting
an LV ejection fraction40% or50% than BNP in the total population and in several male
and age subgroups, whereas areas were equivalent in female subgroups. Age- and gender-
adjusted cutpoints improved test characteristics of NT-proBNP. Both assays detected
patients with systolic and/or moderate to severe diastolic dysfunction to a similar degree,
which was less robust than the detection of LV systolic dysfunction alone.
CONCLUSIONS Amino-terminal pro-BNP in normal patients is affected primarily by gender and age, which
should be considered when interpreting values. Importantly, in the entire population sample
NT-proBNP performed at least equivalently to BNP in detecting LV dysfunction and was
superior in some subgroups in detecting LV systolic dysfunction. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.02547:345–53) © 2006 by the American College of Cardiology Foundation
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hrain natriuretic peptide (BNP) is secreted from the heart
rimarily in response to stretch, and its plasma levels
ncrease in heart failure (HF), in which it aids in diagnosis
nd management (1). We recently reported that age, gen-
er, and left atrial (LA) volume index were independently
ssociated with BNP in normal patients identified from a
andom sample of residents in Olmsted County, Minnesota,
uggesting that age and gender be considered when devel-
ping partition values (2). We also reported that BNP
etected an ejection fraction (EF) 40% in each age and
ender stratum of the random sample with good sensitivity
nd specificity. However, its use as a screening tool for the
eneral population to identify preclinical left ventricular
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iagnostics (Dr. Burnett).A
Manuscript received April 27, 2005; revised manuscript received August 26, 2005,
ccepted September 8, 2005.LV) dysfunction remains to be established (2,3). Other
nvestigators examined the effects of clinical factors influ-
ncing BNP, such as heart rate (HR), obesity (4,5), renal
unction (6,7), and medications such as beta blockers (8)
nd hormone replacement therapy (2).
Amino-terminal pro-BNP (NT-proBNP), the physio-
ogically inactive 1-76 amino acid fragment that is secreted
ith mature 32-amino acid BNP after cleavage from the
rohormone, is an additional biomarker for HF (9–15).
ith a longer plasma half-life, NT-proBNP may behave
ifferently than BNP (16,17). Multiple factors seem to
nfluence NT-proBNP, especially age and gender (13,18).
mportantly, studies are limited that provide an in-depth
omparison of NT-proBNP and BNP in detecting left
entricular systolic dysfunction (LVSD) using a large
opulation-based random sample that has been character-
zed for LVSD and diastolic dysfunction (DD) by detailed
chocardiograms (14,19–25).
Natriuretic peptide secretion may increase with DD, and
tudies have suggested that BNP is increased with LV
ypertrophy or increased LV filling pressures (26–28).
nother study that excluded patients with systolic dysfunc-
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NT-proBNP and Left Ventricular Dysfunction January 17, 2006:345–53ion reported that BNP may detect DD (29). We reported
hat BNP may be suboptimal for screening the general
opulation for DD (3). To the best of our knowledge, there
re no studies comparing NT-proBNP and BNP with
egard to detecting either DD and/or LVSD in a large
andom sample of the general population.
Using our large, well-characterized random sample of
esidents in Olmsted County, Minnesota, we sought to
dentify factors that influenced NT-proBNP and to estab-
ish reference ranges for normal people. In the total popu-
ation sample, we also compared the test characteristics of
T-proBNP and BNP in detecting an EF 40%, an EF
50%, and either LVSD or DD. We hypothesized that
T-proBNP would be influenced by factors similar to those
hat influence BNP and that NT-proBNP is at least as good
diagnostic marker for LV dysfunction as BNP.
ETHODS
he Mayo Institutional Review Board approved this study.
tudy population. Medical records review and detailed
wo-dimensional and color Doppler echocardiography were
one on participating residents (n  2,042, age 45 years)
f Olmsted County, Minnesota, and were previously re-
orted (2), as was DD in this population, which was
lassified as mild, moderate, and severe (3,30). Patients were
onsidered clinically normal when they had no history of
ardiovascular, pulmonary, or renal disease; had no diabetes;
ook no cardiovascular medications; had normal echocardio-
rams for systolic and diastolic function; and were in normal
inus rhythm (2). Participants with LV dysfunction but
ithout a chart history of HF were considered as having
reclinical LV dysfunction (3,31).
ssays. B-type natriuretic peptide was measured by immu-
oassay (Biosite) as previously reported (2). Plasma NT-
roBNP was measured with the Elecsys proBNP electro-
hemiluminescence immunoassay run on the Elecsys 2010
Roche Diagnostics, Indianapolis, Indiana). This sandwich
Abbreviations and Acronyms
AUC  area under the curve
BMI  body mass index
BNP  B-type natriuretic peptide/
brain natriuretic peptide
DD  diastolic dysfunction
EF  ejection fraction
GFR  glomerular filtration rate
HF  heart failure
HR  heart rate
NT-proBNP  amino-terminal pro-B-type natriuretic
peptide
LA  left atrial
LR  likelihood ratio
LV  left ventricular
LVSD  left ventricular systolic dysfunction
ROC  receiver-operating characteristicssay uses two different polyclonal antibodies, one to amino acids 1 to 21 and one to amino acids 39 to 50. The lower
imit of detection is 5 pg/ml with inter-assay and intra-assay
ariabilities of 3.1% and 2.5%, respectively.
nfluence of clinical characteristics. Influences on NT-
roBNP were assessed with univariate and multivariate
nalysis for age, gender, body mass index (BMI), HR, LA
olume index, LV mass index, LV volume index, systolic
nd diastolic blood pressure, serum creatinine, and calcu-
ated glomerular filtration rate (GFR; by Cockcroft-Gault
ormula).
etection of LV dysfunction. The abilities of NT-
roBNP and BNP to identify EF 40%, EF 50%, and
VSD or DD were determined for the total population and
or age/gender-specific strata.
tatistical methods. Because the variability of NT-
roBNP increased with its mean level, the natural log
ransformation was used in the regression analyses to satisfy
odeling assumptions. Nomograms based on age and
ender were established using the least-squares regression fit
f log-transformed NT-proBNP with age and gender as
redictor variables. From the fitted model, the 5th, 50th,
nd 95th percentiles were estimated and back-transformed
o the natural scale. An interaction term with age and
ender was also evaluated to determine whether the associ-
tion of age with NT-proBNP differed between the gen-
ers. The Spearman correlation coefficient was used to
nvestigate the influence of patient characteristics on NT-
roBNP levels in univariate analysis. Linear least-squares
egression with stepwise selection was used to identify those
haracteristics that independently predicted NT-proBNP
evels. Diagnostic abilities of NT-proBNP or BNP were
valuated using receiver-operating characteristic (ROC)
urves. The method described by DeLong et al. (32) was
sed to compare areas under the curve (AUCs) obtained
rom paired assays. The optimal discriminatory value for
ach assay was estimated by the point along the ROC curve
hat provided the minimum Euclidean distance between
hat of a perfect assay with 100% sensitivity and specificity.
he positive likelihood ratio (LR  sensitivity/
1specificity]) and negative likelihood ratio (LR 
1sensitivity]/specificity) were calculated for the optimal
iscriminatory values. Statistical significance was accepted
t p  0.05.
ESULTS
able 1 provides characteristics of the participating patients.
ffect of clinical characteristics on NT-proBNP. The
T-proBNP values were available for 1,869 patients, of
hom 746 were clinically normal. Table 2 reports age- and
ender-specific NT-proBNP. Table 3 summarizes the mul-
ivariate analysis and gives the relative effect of these
ifferent clinical variables on NT-proBNP in the normal
ubgroup as well as for the total population and the
bnormal subgroup.
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January 17, 2006:345–53 NT-proBNP and Left Ventricular DysfunctionIn univariate analysis (supplemental Tables 1 and 2
vailable online), increasing age, calculated GFR (which
ccounts for age), LA volume index, LV dimension index,
nd gender had the highest correlation coefficients with
T-proBNP in the normal subgroup. Correlations were
ignificant but weak for systolic and diastolic blood pressure,
MI, and HR. In the multivariate analysis for normal
atients, female gender and age were the strongest indepen-
ent predictors of higher NT-proBNP, with LA volume
ndex, LV dimension index, and HR contributing only
lightly. When the multivariate analysis was performed in
he abnormal subgroup and in the total population, serum
reatinine, BMI, calculated GFR, and LV mass were also
ound to affect independently NT-proBNP.
When adjusted for age and gender in a multivariate
nalysis, BMI had no significant effect on NT-proBNP in
he normal population (regression coefficient, 0.01; p 
.09). Even when analyzed in BMI categories and adjusted
or age and gender, there was still no effect in the normal
atients (BMI 25 kg/m2: 0.0007, p  0.98; 25  BMI
30 kg/m2: 0.032, p  0.37; BMI 30 kg/m2: 0.002, p
0.89). Multivariate analysis in the abnormal population
howed that BMI inversely but minimally affects NT-
roBNP (0.015, p 0.012). Analyzing this group in BMI
ategories in an age- and gender-adjusted model found that
MI affected non-overweight patients (BMI 25 kg/m2:
0.09, p  0.007) but not individuals with increased BMI
25 kg/m2 BMI30 kg/m2:0.05, p 0.17; BMI30
able 1. Characteristics of the Total Study Population and Subgr
Total Population
(n  1,869)
atient gender
Male, % 48.0
Female, % 52.0
ge, yrs, mean  SD (range) 62  10 (45–96)
ge categories
45–54 yrs, % 29.4
55–64 yrs, % 30.3
65–74 yrs, % 25.6
75 yrs, % 14.7
iabetes, % 7.8
ast or current atrial fibrillation, % 4.7
oronary artery disease, % 12.4
ast heart failure diagnosis, % 2.2
ypertension, % 37.1
besity, BMI 30 kg/m2, % 32.2
MI  body mass index; EF  ejection fraction; SD  standard deviation.
able 2. Age- and Gender-Specific Ranges (5th to 95th Percenti
NT-proBNP
Age 45–54 yrs Age 55–64 y
Median (5th–95th Percentile) Median (5th–95th P
N N
omen 54 (8–141) 77 (17–226)
190 137
en 13 (5–87) 25 (5–88)
187 114Because n  2, actual values are given for reference only.
NT-proBNP  amino-terminal pro-B-type natriuretic peptide.g/m2: 0.012, p 0.35). In multivariate analysis of the total
opulation (normal and abnormal combined), the effect of
MI was inverse but minimal (0.012, p  0.01).
mpact of estrogen and beta-blockers. By univariate anal-
sis, use of estrogen influenced NT-proBNP in normal
atients (p  0.0001), but after accounting for age and
ender it contributed only 3.4% to the model r2 (p 
.0152). In the total population, use of beta-blockers was
ignificant by univariate analysis (p  0.0001), but contrib-
ted only 0.9% of the model r2 (p  0.0017) after adjusting
or age, gender, and cardiac conditions in which beta-
lockers are frequently used.
etection of LVSD. Both NT-proBNP and BNP were
vailable for 1,869 patients. Of these, 37 had an EF 40%
nd 115 had an EF 50%. Of note, 45.9% of those with an
F 40% had preclinical LV dysfunction. Table 4 summa-
izes the estimated AUC, sensitivity and specificity for
T-proBNP and BNP for the total sample and for age- and
ender-specific strata. For detecting an EF 40%, NT-
roBNP had a significantly higher AUC in comparison
ith BNP in the total population and for the subgroups of
ale patients and patients 65 years old. For detecting an
F 50%, the AUC for NT-proBNP was significantly
igher than that for BNP in all patients, patients 65 years
ld, patients 65 years old, male patients, male patients
65 years old, male patients 65 years old, and female
atients 65 years old. There was a tendency for better
etection of an EF 50% in female patients overall (p 
Normal Patients
(n  746)
Patients With EF <40%
(n  37)
47.2 78.4
52.8 21.6
57  9 (45–96) 71  11 (50–89)
47.8 10.8
32.6 18.9
14.9 35.1
4.7 35.1
0 16.2
0 37.8
0 64.9
0 54.1
0 64.9
21.2 54.1
or Plasma NT-proBNP (pg/ml) in Normal Patients
Age 65–74 yrs Age 75–96 yrs
tile) Median (5th–95th Percentile) Median (5th–95th Percentile
N N
114 (25–458) 124 (42–587)
57 18
45 (14–140) 57 (46–68)*
41 2oupsles) f
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NT-proBNP and Left Ventricular Dysfunction January 17, 2006:345–53.09). Figures 1A through 1D depict the ROC curves of
T-proBNP and BNP in detecting an EF 40% for all,
ge 65 years old, male patients, and female patients,
espectively.
To better understand the implications for screening the
eneral population for early LVSD with NT-proBNP as
able 3. Parameters That Significantly Contributed to NT-proBN
Parameters Included
in the Model Regression Coefficient
ormal population
Female gender 1.098
Age 0.041
LA volume index 0.029
LV dimension index 0.373
Heart rate 0.009
otal population
Age 0.052
LA volume index 0.041
Female gender 1.176
Serum creatinine 1.167
LV dimension index 0.441
GFR 0.004
BMI 0.029
LV mass 0.002
bnormal population
Age 0.047
LA volume index 0.041
Female gender 1.057
Serum creatinine 1.409
LV dimension index 0.385
BMI 0.035
GFR 0.004
LV mass 0.003
arameters included in the model that were not significant in any of the subgroups w
his analysis.
BMI  body mass index; GFR  glomerular filtration rate; LA  left atrial; LV
able 4. Test Characteristics for NT-proBNP and BNP for the D
opulation and Subgroups
Population EF n p* AU
ll (n  1,869)  40 37 0.0087 0.9
 50 115 0.0001 0.7
ge 65 yrs (n  747)  40 26 0.0360 0.9
 50 70 0.0011 0.8
ge 65 yrs (n  1,122)  40 11 0.0912 0.9
 50 45 0.0001 0.6
ll men (n  907)  40 29 0.0152 0.9
 50 85 0.0001 0.8
ll women (n  962)  40 8‡ 0.8107 0.9
 50 30 0.0908 0.8
en, age 65 yrs (n  350)  40 20 0.0718 0.9
 50 50 0.0036 0.8
omen, age 65 yrs (n  397)  40 6‡ 0.5178 0.9
 50 20 0.1867 0.8
en, age 65 yrs (n  557)  40 9‡ 0.0921 0.9
 50 35 0.0002 0.6
omen, age 65 yrs (n  565)  40 2‡ 0.3627 0.9
 50 10 0.0278 0.7
p for comparison of AUCs for NT-proBNP and BNP. †The NT-proBNP or BNP
imited number of subjects with EF 40% in this subgroup.
AUC  area under the curve; EF  ejection fraction; NT-proBNP  amino-terminalpposed to BNP, we calculated further test characteristics
ased on the optimal age- and gender-specific cutpoints.
able 5 shows LR and LR, the percentage of patients
creened who would need echocardiography secondary to an
bnormal test result, the percent of echocardiograms that
ould be negative, the percent of those with a reduced EF
alues in Multivariate Analysis
Standard Error Partial r2 p Value
0.082 0.296 0.0001
0.005 0.077 0.0001
0.007 0.025 0.0001
0.146 0.009 0.0109
0.004 0.005 0.0223
0.003 0.296 0.0001
0.003 0.077 0.0001
0.076 0.071 0.0001
0.159 0.018 0.0001
0.107 0.016 0.0001
0.001 0.003 0.0025
0.008 0.003 0.0001
0.000 0.003 0.0012
0.004 0.276 0.0001
0.004 0.074 0.0001
0.095 0.055 0.0001
0.184 0.036 0.0001
0.132 0.019 0.0035
0.009 0.006 0.0002
0.002 0.004 0.0089
0.000 0.003 0.0026
tolic and diastolic blood pressure. The NT-proBNP values were log-transformed for
ft ventricular; NT-proBNP  amino-terminal pro-B-type natriuretic peptide.
tion of Left Ventricular Systolic Dysfunction in the Total
NT-proBNP BNP
Cutpoint† Sens Spec AUC Cutpoint† Sens Spec
228 86.5 86.0 0.89 66 81.1 81.1
129 73.9 73.8 0.72 40 68.7 68.7
452 88.5 88.4 0.87 97 76.9 76.9
233 75.7 75.7 0.79 73 71.4 71.4
163 90.9 90.9 0.88 42 81.8 81.8
59 62.2 61.3 0.56 19 55.6 55.5
209 86.2 87.4 0.91 55 82.8 82.4
92 75.3 74.8 0.73 28 70.6 70.2
372 83.3 83.3 0.94 102 87.5 87.5
246 75.0 73.1 0.77 57 73.3 73.3
462 85.7 88.0 0.89 79 75.0 75.9
211 79.2 79.4 0.82 61 72.0 72.1
372 83.3 83.3 0.88 124 83.3 81.0
246 75.0 73.1 0.78 79 70.0 69.7
109 88.9 90.0 0.90 24 77.8 77.7
32 62.9 62.8 0.58 12 57.1 56.7
245 100 94.3 0.98 108 100 96.4
105 70.0 69.9 0.64 30 60.0 60.0
ntration (pg/ml) resulting in a sensitivity and specificity closest to 100%. ‡Note theP V
ere sysetec
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w
a
f
b
c
t
D
G
N
t
p
b
c
d
d
p
f
w
p
g
y
b
t
i
c
D
D
D
E
E
n
d
m
d
D
W
i
p
c
p
a
g
o
i
d
t
I
p
f
e
e
c
t
F minal
d (A), p
349JACC Vol. 47, No. 2, 2006 Costello-Boerrigter et al.
January 17, 2006:345–53 NT-proBNP and Left Ventricular Dysfunctionho would be missed, and the odds ratio for NT-proBNP
nd BNP. Comparison of the odds ratio for the two assays
or detecting an EF 40% suggests that NT-proBNP may
e superior to BNP for screening certain subgroups, espe-
ially male patients and elderly patients. For female patients,
he two assays perform equivalently.
eveloping age- and gender-specific reference ranges.
iven that age and gender had the greatest impact on
T-proBNP concentrations, age- and gender-specific par-
ition values should help to improve specificity of NT-
roBNP as a screening tool. Table 6 provides cutpoints
ased on discriminatory values derived from the ROC
urves. For younger women (ages 45 to 54 years), no systolic
ysfunction was noted in our population and hence no
iscriminatory values are given. Table 7 reports NT-
roBNP test characteristics for the total, male-only, and
emale-only populations for the detection of an EF 40%
hen using a single optimal cutpoint for the respective
opulation as compared with using optimal age- and
ender-adjusted cutpoints. For this analysis, women
ounger than 65 years of age were treated as a single stratum
ecause of the absence of an EF 40% in women younger
han 55 years old. Age- and gender-adjusted cutpoints
mproved the test characteristics as compared with a single
utpoint.
etection of combined LVSD and moderate to severe
D. Results for both assays and evaluations for LVSD and
igure 1. The receiver operating characteristic (ROC) curves of amino-ter
etecting an ejection fraction (EF)  40% for the entire population (all)D were available for 1,866 patients. Of these, 129 had an fiF 40% and/or moderate to severe DD, and 204 had an
F 50% and/or moderate to severe DD. In this commu-
ity sample, neither assay seemed superior in detecting LV
ysfunction defined as LVSD or DD (see online supple-
ent). In most strata, the AUC decreased as compared with
etecting LVSD only.
ISCUSSION
e report that age and gender were the major factors
nfluencing NT-proBNP plasma concentrations in normal
atients and conclude that age and gender should be
onsidered when establishing normal ranges. The NT-
roBNP was at least as effective as BNP in detecting LVSD,
nd in some subgroups it was superior. Using age- and
ender-adjusted cutpoints improved the test characteristics
f NT-proBNP. Both NT-proBNP and BNP lost sensitiv-
ty and specificity when used to detect LV dysfunction
efined as LVSD or DD, with neither assay outperforming
he other.
mpact of clinical factors on NT-proBNP. In normal
atients, NT-proBNP, like BNP, tends to be higher in
emale patients and older individuals. Reasons for this
levation with age and female gender remain unclear. Kawai
t al. (33) and others have suggested a reduction in the
learance receptor for BNP with aging (33–36). Alterna-
ively, increased production with age could explain the
pro-B-type natriuretic peptide (NT-proBNP) (red) and BNP (green) for
atients 65 years old (B), male patients (C), and female patients (D).ndings. Regarding gender, hormone replacement therapy
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NT-proBNP and Left Ventricular Dysfunction January 17, 2006:345–53as associated with higher BNP levels in women, suggest-
ng that estrogen status may be partly responsible (2). In
ddition, as with BNP, LA volume index and LV dimen-
ion index had slight, independent associations with NT-
roBNP in normal patients, reflecting atrial as well as
entricular production (37–40).
We found no independent correlation between serum
reatinine or calculated GFR and NT-proBNP in normal
atients. Because NT-proBNP does not have a clearance
eceptor (41), some suggested that clearance for NT-
roBNP may be renal and influenced by renal function (42).
thers have reported no interdependence between renal
mpairment and elevated NT-proBNP (43). Our data sug-
est that the impact is minor if the degree of renal
ysfunction is small and if factors such as age and gender are
onsidered.
Regarding obesity, when normal patients, abnormal pa-
ients, and the total population were analyzed separately, the
mpact of BMI on NT-proBNP values was minimal in
omparison with the effects of age and gender. Wang et al.
44) reported a tendency for an inverse relationship between
NP and BMI in a non-obese, healthy subgroup of the
ramingham Heart Study offspring cohort, and an inverse
able 5. Test Characteristics for NT-proBNP and BNP for the D
ubgroups
Population EF LR* LR*
% Screen
Echoca
ll 40 6.2/4.3 0.16/0.23 15.
50 2.8/2.2 0.35/0.46 29.
ge 65 yrs 40 7.6/3.3 0.13/0.30 12.
50 3.1/2.5 0.32/0.40 29.
ge 65 yrs 40 10.0/4.5 0.10/0.22 11.
50 1.6/1.2 0.62/0.80 39.
ll men 40 6.8/4.7 0.16/0.21 15.
50 3.0/2.4 0.33/0.42 29.
ll women 40 5.0/7.0 0.20/0.14 17.
50 2.8/2.7 0.34/0.36 28.
en, age 65 yrs 40 7.1/3.1 0.16/0.33 16.
50 3.8/2.6 0.26/0.39 29.
omen, age 65 yrs 40 5.0/4.4 0.20/0.20 17.
50 2.8/2.3 0.34/0.43 29.
en, age 65 yrs 40 8.9/3.5 0.12/0.29 11.
50 1.7/1.3 0.59/0.76 38.
omen, age 65 yrs 40 17.5/27.8 0/0 6.
50 2.3/1.5 0.43/0.67 30.
NT-proBNP/BNP.
EF  ejection fraction; LR  positive likelihood ratio; LR  negative likeli
able 6. NT-proBNP Cutpoints, Sensitivity, and Specificity for A
raction  40%
Age
Men
NT-proBNP Sens
5–54 yrs 108 100
5–64 yrs 234 100
5–74 yrs 462 91
75 yrs 1,024 89utpoints are based on optimal discriminatory value obtained from stratum-specific ROC
ND  not determined; NT-proBNP  amino-terminal pro-B-type natriuretic peptideelationship in another study that included overweight and
bese patients (4). Similarly, BMI was an independent
egative correlate of BNP in HF patients (5). Although
MI may negatively impact NT-proBNP, the degree is not
s impressive as that of age and gender.
mino-terminal pro-BNP in detection of LV dys-
unction. Amino-terminal pro-BNP identified those with
F 40% with high sensitivity and specificity. When
omparing ROC curves, NT-proBNP was superior or equal
o BNP in detecting an EF 40%, especially for the entire
tudy population, male patients, and persons 65 years of
ge. The number of women with an EF 40% in this
opulation was small, and in general, no significant differ-
nce could be found between the two assays in the female
ubgroups. Given the small number of individuals with EF
40% in the subcategories of female patients65 years old,
emale patients65 years old, all female patients combined,
nd male patients65 years old, one is cautious in reporting
esults in these groups. This is a limitation of using a general
opulation sample rather than a selected diseased popula-
ion. We also showed that age- and gender-adjusted cut-
oints further improved the test characteristics of NT-
roBNP in detecting an EF 40%.
tion of Systolic Dysfunction in the Total Population and
eeding
ram*
% Echocardiograms
That Are Negative*
% With Disease
Missed* Odds Ratio*
88.9/92.0 13.5/18.9 39.4/18.4
84.4/87.4 26.1/31.3 8.0/4.8
89.8/95.3 11.5/23.1 58.6/11.1
75.6/79.5 24.3/28.6 9.7/6.2
80.8/90.4 9.1/18.2 99.8/20.2
93.7/95.0 37.8/44.4 2.6/1.6
81.6/86.6 13.8/17.2 43.3/22.5
76.4/80.3 24.7/29.4 9.0/5.7
96.0/94.5 16.7/12.5 24.9/49.0
91.8/91.9 25.0/26.7 8.2/7.5
69.8/84.1 14.3/25.0 43.9/9.4
60.9/69.9 20.8/28.0 14.7/6.6
92.9/93.7 16.7/16.7 24.9/21.3
87.1/89.0 25.0/30.0 8.2/5.4
87.3/94.6 11.1/22.2 72.1/12.2
89.8/91.9 37.1/42.9 2.9/1.7
94.1/91.0 0/0 –/–
95.8/97.4 30.0/40.0 5.4/2.3
atio.
nd Gender Strata for the Detection of an Ejection
Women
c NT-proBNP Sens Spec
ND ND ND
246 100 90
773 100 98
879 75 86etec
ed N
rdiog
4/20.1
1/33.6
7/23.9
1/32.6
0/19.7
6/44.9
0/19.7
9/33.6
3/13.1
4/28.2
2/27.0
0/34.2
7/20.0
3/32.3
3/23.2
8/44.2
0/3.9
8/40.4ge a
Spe
96
94
94
84curves.
; Sens  sensitivity; Spec  specificity.
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January 17, 2006:345–53 NT-proBNP and Left Ventricular DysfunctionUsing this population sample, we previously examined
NP as a screening test in patients with preclinical LV
ysfunction. Considering the prevalence of preclinical
VSD or DD, screening with BNP for asymptomatic
isease was considered suboptimal, requiring confirmatory
chocardiography (3). Heidenreich et al. (45) reported that
creening asymptomatic patients with BNP, followed by
chocardiography in patients with an abnormal test result,
ncreased lifetime cost of care and improved outcome for
en but not women. Specifically, for populations with a
educed EF prevalence of 1%, this screening strategy may
rovide a health benefit at a cost comparable to or less than
hat of other accepted interventions (45). The cost-
ffectiveness of NT-proBNP for detecting a reduced EF
emains to be determined.
Amino-terminal pro-BNP and BNP performed similarly
or the detection of LV dysfunction of any type (systolic or
iastolic), both losing sensitivity and specificity. This loss of
ensitivity and specificity when DD is included may be
eflective of the influence of chamber “stretch” (as seen in
VSD) as opposed to chamber stiffness or hypertrophy (as
een in DD). Thus, stretch may be more important with
espect to stimulating secretion of natriuretic peptides.
ifferences in NT-proBNP and BNP immunoassays.
he immunochromatographic Biosite Triage BNP assay
ecognizes amino acids 1 through 32 of BNP and was
pproved as a point-of-care device (24). It correlates rela-
ively well with the automated Roche NT-proBNP assay,
lthough the results are not directly interchangeable (46).
he NT-proBNP assay does not cross-react with BNP and
s precise over a wide range (30 to 35,000 ng/l) (24). This
recision may explain its higher efficacy for detecting
educed EF in selected groups compared with the Biosite
NP. Alternatively, the reported greater stability of NT-
roBNP in plasma may be a factor. Also, NT-proBNP may
ave lower intraindividual and interindividual variation than
iosite BNP (47).
erspective. Three smaller studies have compared BNP
nd NT-proBNP in detecting reduced EF in the general
opulation or in cardiac patients. Hobbs et al. (25) reported
hat BNP and NT-proBNP detected 33 patients with
VSD equivalently in 591 prospective patients of the
eneral population. In 339 patients hospitalized for angiog-
aphy, Pfister et al. (14) reported similar AUCs for detecting
VSD for NT-proBNP and BNP. Seino et al. (48) reported
hat in 105 chronic HF patients and 67 normal patients,
oth NT-proBNP and BNP progressively increased in
roportion to New York Heart Association functional class,
ith the increment being greater for NT-proBNP than
NP. The AUCs were similar for detecting an EF 40%,
ut tended to be greater for NT-proBNP for the detection
f EF 50%, suggesting that NT-proBNP may be a more
iscerning marker for HF detection than BNP.
Our studies benefited from a robust number of patients
ndergoing BNP, NT-proBNP, and comprehensive echo-
cardiography, and support the conclusion that both BNPTa
b
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NT-proBNP and Left Ventricular Dysfunction January 17, 2006:345–53nd NT-proBNP can detect reduced EF. In some sub-
roups, especially male patients and elderly patients, NT-
roBNP may be superior to BNP in detecting LVSD.
hen applied to the identification of patients with LVSD
nd/or moderate to severe DD, there was a decrease or
eutral effect on the test characteristics of both assays in all
ubgroups.
A limitation of this study is that because of the limited
umber of patients with a reduced EF, we did not differ-
ntiate between clinical HF and preclinical LV dysfunction
or the screening analysis. Of note, the AUCs for detecting
n EF 40% for NT-proBNP were similar if patients with
nown HF were excluded (all, 0.95; age 65 years, 0.91;
ge 65 years, 0.98; male patients, 0.95; female patients,
.98; male patients age 65 years, 0.91). A larger study is
eeded and seems warranted to determine more definitively
he diagnostic characteristics of NT-proBNP.
In summary, gender and age were the major factors
nfluencing NT-proBNP in normal patients, with other
linical factors only minimally contributing. We conclude
hat in this community sample of patients 45 years old,
T-proBNP detects an EF40% with good sensitivity and
pecificity and has a performance that is superior or equiv-
lent to that of BNP. The test characteristics of NT-
roBNP are further improved when age- and gender-
djusted cutoffs are used.
eprint requests and correspondence: Dr. Lisa C. Costello-
oerrigter, Cardiorenal Research Laboratory, Guggenheim 915,
ayo Clinic and Mayo Clinic College of Medicine, 200 First
treet SW, Rochester, Minnesota 55905. E-mail: costello.
isa@mayo.edu.
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